Zobrazeno 1 - 10
of 160
pro vyhledávání: ''
Autor:
Junji Tsurutani, Iori Taki-Takemoto, Kaori Nakatani, Motoi Ohba, Tohru Ohmori, Toshimitsu Yamaoka, Ken-Ichi Fujita, Daisuke Kamei, Satoru Arata, Shinichi Iwai, Sojiro Kusumoto
Publikováno v:
Molecular Cancer Therapeutics. 18:112-126
The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs
Autor:
Gregory J. Riely, Marc Ladanyi, Ryan Kim, Ken Suzawa, Matthew D. Hellmann, Helena A. Yu, Maria E. Arcila, Ahmet Zehir, Ai Ni, Bob T. Li, Michael F. Berger, Romel Somwar, Emmet Jordan, Mark G. Kris, David B. Solit
Publikováno v:
Clinical Cancer Research. 24:3108-3118
Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR-mutant tumors prior to treatment and after progression on
Publikováno v:
Cancer Research. 81:1431-1431
Osimeritinib (OR), a Tyrosine Kinase Inhibitor is a first-line therapy in EGFR-mutant NSCLC patients. Resistance to OR treatment may occur due to acquired C797S mutations, MET amplifications and ALK rearrangements and other mechanisms not clearly def
Autor:
Christian A. Hassig, Nam-Phuong Nguyen, Dean Perusse, Kristen M. Turner, Jason Christiansen, Laurence Jadin
Publikováno v:
Cancer Research. 81:1089-1089
Introduction: Tumors with oncogene copy number amplification are aggressive, have poor prognosis and, to date, have been very difficult to treat. Computational analyses in a large pan-cancer study revealed that ecDNA comprises over 50% of highly ampl
Autor:
Ana Rita Oliveira, José Carlos Machado, Joana Marques, Susana Junqueira-Neto, José Luis Costa, Sonia A. Melo
Publikováno v:
Cancer Research. 81:1099-1099
Targeted therapies almost universally fail due to the development of resistance. EGFR-mutant non-small cell lung cancer (NSCLC) is a well characterized model of such mechanism. In this model, treatment with anti-EGFR therapy leads to resistance drive
Autor:
Lukas C. Heukamp, William Pao, Helen Pasternack, Christian Becker, Kerstin Albus, Matthias Scheffler, Reinhard Buettner, Johannes M. Heuckmann, Alexandra Florin, Martin L. Sos, Andreas H. Scheel, Jana Fassunke, Martin Peifer, Thorsten Persigehl, Sabine Merkelbach-Bruse, Sebastian Michels, Marc Bos, Lynnette Fernandez-Cuesta, Janine Altmüller, Dennis Plenker, Jürgen Wolf, Lydia Meder, Sandra Ortiz-Cuaran, Johannes Berg, llona Dahmen, Michaela Angelika Ihle, Carina Heydt, Hongbin Ji, Rieke Fischer, Roman K. Thomas, Christian Müller, Peter Nuernberg, Sascha Ansén, Christine M. Lovly, Hans-Ulrich Schildhaus, Katharina König
Publikováno v:
Clinical Cancer Research. 22:4837-4847
Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). Experimental Design: We analyzed tumor biopsies f
Autor:
Takatsugu Okegawa, Shuta Tomida, Suguru Hamada, Kikuo Nutahara, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Kazuto Nishio, Yu Nakamura, Yosuke Togashi, Yoshihiko Fujita, Eri Banno, Marco A. De Velasco, Hirokazu Nakahara
Publikováno v:
Molecular Cancer Therapeutics. 15:1988-1997
The prognosis for patients with advanced esophageal or head-and-neck squamous cell carcinoma (ESCC or HNSCC) remains poor, and the identification of additional oncogenes and their inhibitors is needed. In this study, we evaluated the sensitivities of
Autor:
Imad Shureiqi
Publikováno v:
Cancer Prevention Research. 11:1-3
Patients with familial adenomatous polyposis (FAP) have an increased risk of developing duodenal adenomas and adenocarcinomas. In previous trials, sulindac (a cyclooxygenase inhibitor) alone failed to significantly suppress duodenal tumorigenesis in
Autor:
Ryan J. Hartmaier, Martin Johnson, Helen Tomkinson, Ganesh Mugundu, James Dunyak, Aleksandra Markovets, Juliann Chmielecki, Karthick Vishwanathan, Carl Barrett, Philip Overend
Publikováno v:
Cancer Research. 80:CT024-CT024
Circulating tumor DNA is released into the bloodstream from tumors and can reflect both intra-tumor heterogeneity and clonal evolution.1 As ctDNA levels are thought to reflect tumor burden, a decrease in ctDNA while on therapy may suggest treatment e
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1